Ertugliflozin Brand names: Steglatro

What is ertugliflozin used for?

From the label: indications and usage

STEGLATRO ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. STEGLATRO is a sodium glucose co-transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use: Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. ( 1 ) Limitations of Use Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [see Warnings and Precautions (5.1) ].

Conditions named in the indications of ertugliflozin's FDA labels, with every medicine labeled for each:

• Type 2 diabetes

What does the patient leaflet for ertugliflozin say first?

The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.

From the patient leaflet: What is the most important information I should know about STEGLATRO?

STEGLATRO may cause serious side effects, including: Diabetic ketoacidosis (increased ketones in your blood or urine) in people with type 1 diabetes and other ketoacidosis. STEGLATRO can cause ketoacidosis that can be life-threatening and may lead to death. Ketoacidosis is a serious condition which needs to be treated in a hospital. People with type 1 diabetes have a high risk of getting ketoacidosis. People with type 2 diabetes or pancreas problems also have an increased risk of getting ketoacidosis. Ketoacidosis can also happen in people who: are sick, cannot eat or drink as usual, skip meals, are on a diet high in fat and low in carbohydrates (ketogenic diet), take less than the usual amount of insulin or miss insulin doses, drink too much alcohol, have a loss of too much fluid from the body (volume depletion), or who have surgery. Ketoacidosis can happen even if your blood sugar is less than 250 mg/dL. […] Seek medical attention immediately if you have a fever or you are feeling very weak, tired or uncomfortable (malaise), and you develop any of the following symptoms in the area between and around your anus and genitals: pain or tenderness swelling redness of skin (erythema) Also tell your healthcare provider if you have any of these signs or symptoms of urinary tract infections or yeast infections: Urinary tract infection: burning feeling when you urinate need to urinate often or right away pain in the lower part of your stomach (pelvis) blood in your urine You may also have a fever, back pain, nausea, or vomiting. […]

From the patient leaflet: How should I store STEGLATRO?

Store STEGLATRO at room temperature between 68°F to 77°F (20°C to 25°C). Keep STEGLATRO dry. Keep STEGLATRO and all medicines out of the reach of children.

Is there a generic for ertugliflozin (Steglatro)?

The FDA approved the first generic ertugliflozin on July 13, 2023. 3 generic applications are approved; 0 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.

The Orange Book lists 1 patent for Steglatro tablets: the compound patent runs to December 19, 2031. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.

What do pharmacies pay for ertugliflozin (Steglatro)?

In CMS's NADAC survey of October 7, 2026, pharmacies paid $11.44 per Steglatro 15 mg tablet, about the same as a year earlier. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.

Has ertugliflozin been recalled?

The FDA's Enforcement Report lists 1 recall naming ertugliflozin since 2021: 0 Class I (the most serious), 1 Class II, 0 Class III; 0 still ongoing. A recall names products and lots, not every product of the medicine.

What does the ertugliflozin label say about other medicines?

The ertugliflozin label names 1 other medicine in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.

Check ertugliflozin against other medicines

What do FAERS reports show for ertugliflozin?

The FDA Adverse Event Reporting System holds 1,091 reports that list ertugliflozin among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 12 are coded as a death and 319 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.

Reports received each year

• 0
• 2
• 132
• 280
• 95
• 81
• 96
• 112
• 116
• 124
• 52

• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

The most reported reactions

• Nausea (named in the label)88
• Product Dose Omission Issue (a use or a product term, not a reaction)71
• Urinary Tract Infection (named in the label)65
• Vomiting (named in the label)61
• Fungal Infection58
• No Adverse Event (a use or a product term, not a reaction)56
• Diabetic Ketoacidosis (named in the label)53
• Blood Glucose Increased50

Side effects: the label's list and every FAERS reaction

What else is labeled for the same conditions as ertugliflozin?

31 other medicines are given the same way (oral) and in the same FDA class as ertugliflozin or labeled mainly for the same use (type 2 diabetes), the same class first. Type 2 diabetes lists all 52 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.

Every medicine labeled for the same conditions as ertugliflozin

What next?

Alternatives to ertugliflozin

31 medicines for the same use

Ertugliflozin side effects

the label's list beside FAERS reports

Check an interaction

what two or more labels say about each other